- FDA approves Orca Bio’s cell therapy to improve transplant outcomesThe FDA gave the go-ahead to Orca Bio’s T cell therapy that would reduce transplant-related complications for blood cancer patients. The therapy will be branded as Tregzi, an homage to the regula…Endpoints · 26d ago↗ source
- BridgeBio adds $1B as it prepares three more drug launchesBridgeBio Pharma has reloaded with about $1 billion in a preferred equity deal to bolster its reserves ahead of three potential drug launches over the next year. The California biotech, which for…Endpoints · 26d ago↗ source
- 92Bio revives a T cell engager it had transferred to AmgenA small California startup is reviving an experimental T cell engager that its scientists originally developed but had handed off to Amgen years ago. After repeatedly saying it would bring the drug…